Beckley Psytech made headlines this week when they announced the closing of an oversubscribed Series B financing, raising around $80m to advance their low-dose psilocybin and 5-MeO-DMT programs. Elsewhere, Bright Minds Biosciences reported positive preclinical results, suggesting that their proprietary 5-HT2C agonist may be efficacious in reducing seizure duration and frequency in a rare…


Previous articlePTSF73 – Origin Stories, Complexity, and Transpersonal Psychology
Next articleNavigating Psychedelics for Clinicians and Therapists – Q+A